T Cell Non-Hodgkin Lymphoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	nelarabine Sensitive: A1 - Approval Businesswire - 3 weeks (New A1) nelarabine Sensitive : A1 Businesswire - 3wk	nelarabine Sensitive: A1 - Approval Businesswire - 3 weeks nelarabine Sensitive : A1 Businesswire - 3 weeks - (New A1)
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	bexarotene oral Sensitive: A1 - Approval bexarotene oral Sensitive : A1	bexarotene oral Sensitive: A1 - Approval bexarotene oral Sensitive : A1
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	pralatrexate Sensitive: A1 - Approval pralatrexate Sensitive : A1	pralatrexate Sensitive: A1 - Approval pralatrexate Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1
IL2RA expression	Cutaneous T-cell Lymphoma	IL2RA expression	Cutaneous T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2	cyclophosphamide Sensitive: A2 - Guideline cyclophosphamide Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2	cyclophosphamide + etoposide IV Sensitive: A2 - Guideline cyclophosphamide + etoposide IV Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
TNFRSF8 positive	Peripheral T-cell Lymphoma	TNFRSF8 positive	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	EPOCH Sensitive: A2 - Guideline EPOCH Sensitive : A2	EPOCH Sensitive: A2 - Guideline EPOCH Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	DHAX Sensitive: A2 - Guideline DHAX Sensitive : A2	DHAX Sensitive: A2 - Guideline DHAX Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2	DHAP Sensitive: A2 - Guideline DHAP Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	cyclosporine Sensitive: A2 - Guideline cyclosporine Sensitive : A2	cyclosporine Sensitive: A2 - Guideline cyclosporine Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	romidepsin Sensitive: A2 - Guideline romidepsin Sensitive : A2	romidepsin Sensitive: A2 - Guideline romidepsin Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	ICE Sensitive: A2 - Guideline ICE Sensitive : A2	ICE Sensitive: A2 - Guideline ICE Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2	GemOx Sensitive: A2 - Guideline GemOx Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	GDP Sensitive: A2 - Guideline GDP Sensitive : A2	GDP Sensitive: A2 - Guideline GDP Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	GVD Sensitive: A2 - Guideline GVD Sensitive : A2	GVD Sensitive: A2 - Guideline GVD Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	ESHAP Sensitive: A2 - Guideline ESHAP Sensitive : A2	ESHAP Sensitive: A2 - Guideline ESHAP Sensitive : A2

T Cell Non-Hodgkin Lymphoma

Associations(92)

Associations
(92)